The 8 most recent market catalysts affecting $DCGO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 18, 2026
Corporate Catalyst
Bearish
Impact 85
DocGo shares are trading lower after the company reported worse-than-expected Q2 financial results and narrowed its FY2026 sales guidance.
This headline represents a significant corporate catalyst for DocGo (DCGO). The combination of missing Q2 earnings expectations and, more critically, narrowing the FY2026 sales gui…
Aug 18, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
This filing details pre-market trading activity for 12 healthcare stocks, with six experiencing gains and six experiencing losses. The movements are significant, with Amylyx Pharma…
Aug 17, 2026
Corporate Catalyst
Neutral
Impact 92
Transcript: DocGo Q2 2026 Earnings Conference Call
DocGo announced a definitive agreement to acquire Hicuity Health, a virtual care provider, which is its largest acquisition to date. This is a significant corporate catalyst as it …
Aug 17, 2026
Corporate Catalyst
Neutral
Impact 85
DocGo Signs Agreement To Acquire Hicuity Health; Hicuity Health Shareholders To Get 2% Of DocGo's Common Shares
DocGo has announced its intent to acquire Hicuity Health, a leading provider of telehealth services. This strategic move is significant because it allows DocGo to expand its existi…
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 75
DocGo Narrows FY2026 Sales Guidance from $300.000M-$315.000M to $305.000M-$310.000M vs $306.281M Est
DocGo's 8-K filing discloses a narrowed sales guidance for FY2026. The previous range was $300M-$315M, and the new range is $305M-$310M. This change is significant because it provi…
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 95
DocGo Q2 EPS $(0.16) Misses $(0.06) Estimate, Sales $73.425M Miss $75.404M Estimate
DocGo's Q2 earnings per share of $(0.16) significantly missed the $(0.06) estimate, representing a 166.67% miss and a 45.45% decrease from the prior year. Additionally, sales of $7…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 65
DocGo Likely To Report Narrower Q2 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
The filing details analyst consensus for DocGo's Q2 earnings, projecting a loss of 15 cents per share (narrower than last year) on $75.57 million in revenue (down from last year). …
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
DocGo Granted Additional 180-Day Nasdaq Extension Through Jan. 25, 2027 To Regain Compliance
DocGo (DCGO) has been granted an additional 180-day extension by Nasdaq to regain compliance with listing requirements, extending the deadline to January 25, 2027. This is a signif…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.